ADCelerate is a new, branded solution for antibody-drug conjugate drug development
Piramal Pharma Solutions announced the launch of ADCelerate, a new, branded solution for antibody-drug conjugate drug development that accelerates timelines for developing the initial clinical supply of both drug substances and drug products.
With ADCelerate, Piramal Pharma Solutions (PPS) delivers fully developed manufacturing processes for antibody-drug conjugate drug substances and lyophilised drug products, all within as few as twelve months. The programme includes qualified, Phase I appropriate analytical methods to support batch release and stability studies for both drug substance and drug product, as well as initial stability data on drug substance (six months) and drug product (one month).
Peter DeYoung, CEO, Piramal Pharma Solutions said, “As a CDMO serving the biopharma industry, we recognise that speed matters. Getting our clients into the clinic as quickly as possible without compromising quality supports our ethos of patient-centricity. ADCelerate is a strong example of this principle brought to life. By leveraging our capabilities and expertise in ADCs and sterile fill/finish, we can shorten timelines while maintaining the highest standards of quality.”
The accelerated timelines that ADCelerate delivers are made possible by PPS’s vast experience in antibody-drug conjugate problem solving, as well as the company’s expertise in manufacturing lyophilised drug products. While based on a standard process, all ADCelerate programmes are customised to the scope of each client’s project.
